Surgical Site Infection Clinical Trial
— Early 2RISOfficial title:
Early Recognition and Response to Increases in Surgical Site Infections Using Optimized Statistical Process Control Charts
Verified date | March 2020 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this quality improvement study is to measure the effectiveness of surveillance
using optimized statistical process control (SPC) methods and feedback on rates of surgical
site infection (SSI) compared to traditional surveillance and feedback.
The primary objective is to determine if hospital clusters randomized to receive feedback
from optimized SPC surveillance methods collectively have lower rates of SSI compared to
hospital clusters randomized to receiving feedback from traditional surveillance methods.
Secondary objectives are 1) to estimate and compare the number of signals identified using
optimized SPC methods and traditional surveillance methods; 2) to estimate and compare the
time and effort required to investigate signals generated using optimized SPC methods and
traditional surveillance methods; and 3) to estimate the number and proportion of
false-positive signals identified using optimized SPC methods and traditional surveillance
methods.
The Early 2RIS study will be a prospective, multicenter cluster randomized controlled trial
using stepped wedge design. The active component of the quality improvement study will be
performed in 29 DICON hospitals over three years, from March 2017 through February 2020.
Clusters randomized to intervention will receive feedback on increasing rates of SSI
identified through optimized SPC methods. This intervention is expected to decrease the
subsequent rate of SSIs by closing the feedback loop on SSI outcomes.
Participating study hospitals will all be members of DICON, a network of 43 community
hospitals in North Carolina, South Carolina, Georgia, Florida, and Virginia that provides
community hospitals access to consultative services from infection prevention experts, data
analyses and benchmarking, and educational materials designed by faculty from Duke. This
study is considered part of routine quality improvement measures and a part of previously
established agreements between DICON and the community hospitals. Data flow and communication
are outlined in detail in approved protocols determined to be exempt research by the DUHS
IRB. Briefly, existing clinical data are extracted from participating hospitals' electronic
medical record into discrete files according to DICON specifications. Then a
de-identification process removes direct patient identifiers into a limited dataset.
The majority of data collection will occur through methods already developed and utilized by
study hospitals. In brief, each hospital routinely submits limited datasets to the DICON
Surgical Surveillance Database, including the following variables: hospital, type of
procedure, patient identifier, date of procedure, age, sex, surgeon identifier, start/stop
times, ASA score, wound class, risk index, SSI (Yes/No), date of infection, type of SSI,
location at diagnosis and organism. No identifiable patient or surgeon data are transmitted
to the DICON Surgical Database. Data definitions and data collection methods are standardized
across DICON hospitals. Following signal adjudication, additional data will be collected in a
REDCap database to document actions and rationale.
Status | Completed |
Enrollment | 29 |
Est. completion date | February 29, 2020 |
Est. primary completion date | February 29, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - All patients who undergo one of 13 targeted procedures in 29 DICON study hospitals will be eligible for inclusion. The 13 targeted procedures include coronary artery bypass graft, cardiac valve replacement, colon surgery, herniorrhapy, knee arthroplasty, hip arthroplasty, Cesarean section, abdominal hysterectomy, vaginal hysterectomy, spinal fusion, laminectomy, carotid endarterectomy, and peripheral venous bypass. These procedures were selected because they are frequently performed in community hospitals and/or are associated with particularly adverse outcomes if complicated by SSI. Eligible procedures will be categorized by procedure type at each hospital using ICD9 codes published by the NHSN, per routine DICON activities. Six clusters were constructed from these procedures to ensure that surgeons who perform similar types of procedures were grouped together to limit potential bias. These clusters are labeled as Spine, GI, OB/GYN, Ortho, Vascular, and Cardiac. These clusters are the units for randomization and analysis. Exclusion Criteria: - DICON hospitals that did not submit a letter of support for participating in the study will be excluded. Patients not undergoing one of these 13 procedure types at the 29 study hospitals will be excluded from the analysis. |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Health System | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | Agency for Healthcare Research and Quality (AHRQ) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Differences in rates of SSI. | SSI rate will be calculated as number of SSI/100 procedures per month SSIs will be defined using standard NHSN definitions DICON personnel train local infection preventionists about how to use and interpret SSI definitions. Thus, standard definitions and methods are used at all study hospitals. Cluster-level risk adjustment will be performed using median surgical volume and median NHSN Risk Index (an operation- and patient-specific risk score that predicts SSI) per cluster. |
SSIs can be diagnosed up 30 to 90 days following the procedure, depending on the type of procedure | |
Secondary | Proportion of SSIs determined to be potentially preventable | Among SSIs investigated, each will be provided a "preventability score" after reviewing if best practices were followed. | diagnosed up 30 to 90 days following the procedure, depending on the type of procedure | |
Secondary | Description of and difference in number and type of signals | Signals identified using optimized SPC will be compared to signals identified using standard surveillance; Not a patient-specific outcome | 36 months (entire study period) | |
Secondary | Difference in number of outbreaks identified | Outbreaks identified using optimized SPC will be compared to outbreaks identified using standard surveillance; Not a patient-specific outcome | 36 months (entire study period) | |
Secondary | Difference in number of investigations of increased rates of SSI | Signals may or may not lead to subsequent investigation. Investigators will compare the number of investigations performed following the use of optimized SPC to the number of investigations performed following the use of standard surveillance; signals identified using standard surveillance; Not a patient-specific outcome | 36 months (entire study period) | |
Secondary | Total number and differences in proportion of signals that led to investigations | Signals may or may not lead to subsequent investigation. Investigators will compare the number of investigations performed following the use of optimized SPC to the number of investigations performed following the use of standard surveillance; signals identified using standard surveillance; Not a patient-specific outcome | 36 months (entire study period) | |
Secondary | Time required to investigate signals | Investigators will monitor the time required to investigate signals and compare the time required following the use of optimized SPC methods to the time required following the use of standard surveillance; not a patient-specific outcome | 36 months (entire study period) | |
Secondary | Timing of signals | Investigators will determine how promptly the different surveillance strategies identify signals and compare average/median time to signal between the two study arms; not a patient-specific outcome | 36 months (entire study period) | |
Secondary | Time to completion of investigation | Investigators will determine the time required to complete investigations | 36 months (entire study period) | |
Secondary | Strength and type of signals | Investigators will compare the strength and types of signals generated from each type of surveillance with subsequent adjudication and intervention. | 36 months (entire study period) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04096885 -
The Inselspital Surgical Cohort Study
|
||
Terminated |
NCT03820648 -
Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT04067843 -
Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
|
N/A | |
Terminated |
NCT04042077 -
Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections
|
Phase 3 | |
Completed |
NCT05841576 -
Anaesthetic Management Guided by COMET Measurements
|
N/A | |
Withdrawn |
NCT05338281 -
NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT01697748 -
Prospective Study on Cesarean Wound Outcomes
|
N/A | |
Terminated |
NCT01789697 -
Text Message Study
|
N/A | |
Recruiting |
NCT05966961 -
Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery
|
||
Recruiting |
NCT05077592 -
Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections
|
Phase 4 | |
Recruiting |
NCT05763602 -
PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)
|
Phase 4 | |
Recruiting |
NCT05502380 -
Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery
|
Phase 3 | |
Recruiting |
NCT03221023 -
Intrawound Vancomycin Prophylaxis for Neural Stimulator
|
Phase 2/Phase 3 | |
Completed |
NCT03257202 -
Topical Treatment and Prevalence of P. Acnes
|
Phase 2 | |
Completed |
NCT06154720 -
Surgical Site Infection After Episiotomy Repair Related to Routine Use of Antibiotic Prophylaxis in Low-Risk Population
|
||
Not yet recruiting |
NCT06465901 -
A Stratified, Multi-ARm, muLti-site Randomised Platform Trial Aiming to Reduce the INcidence of Post-operative SSI
|
N/A | |
Not yet recruiting |
NCT04820075 -
Efficacy of an Intervention to Improve the Preoperative Shower in Scheduled Surgery
|
N/A | |
Recruiting |
NCT03561376 -
Zinc Oxide Versus Petrolatum Following Skin Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT04496180 -
Prevena to Prevent Surgical Site Infection After Emergency Abdominal Laparotomy
|
N/A |